Grass & Birch Allergy Phase II Parallel Studies

About the Case Study Pharm-Olam was contracted to provide a full-service solution for two Phase II, dose escalation allergy studies that required a total of 500 patients in Europe and were run in parallel. With two different indications required, Grass Pollen Allergy and Birch Pollen Allergy, Pharm-Olam completed a comprehensive feasibility program and presented the […]

Indolent NHL Immuno-Oncology Rescue Study

Background Non-Hodgkin’s Lymphoma (Indolent NHL, PI3K inhibitor) Allucent was contracted to provide rescue study services by a small-emerging biotech company after the originally contracted CRO had difficultly enrolling patients in the challenging indication of refractory, indolent NHL (Follicular Lymphoma, Marginal Zone Lymphoma, or Small Lymphocytic Lymphoma), as well as other quality issues. Allucent set up […]